IP Library Granted Patent US 11,801,278
Granted Patent B2
US 11,801,278 · App. 17/193,261 · Granted Oct 31, 2023

Method for obtaining an extract of a plant biomass

Inventors: Robert Davidson (Oxnard, CA); Vered Gigi (Oxnard, CA); Jose Bernardo (Oxnard, CA)
A61K36/185A61K31/4045A61K31/675A61K36/07A61K2236/15A61K2236/31A61K2236/37A61K2236/51A61K2236/53A61K2236/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,801,278
App. No.
17/193,261
Granted
Oct 31, 2023
Kind
B2
Abstract

Provided herein is a method of obtaining an extract from a plant biomass as well as an extract obtained from the method. Also provided is a pharmaceutical product, ODF, nutraceutical product, and/or edible product, that includes the extract and one or more excipients. Also provided is a method that includes orally administering the extract (or pharmaceutical product, ODF, nutraceutical product, and/or edible product, that includes the extract).

Claims (48)

1. A method for obtaining an extract, the method comprising:

(a) reducing the size of a plant biomass, the plant biomass comprising psilocybin mushroom and cannabis;

(b) ultrasonicating the plant biomass;

(c) contacting the plant biomass with a supercritical fluid solvent system above the critical pressure and above the critical temperature; and

(d) removing the supercritical fluid solvent system from the plant biomass to obtain an extract of psilocybin mushroom and cannabis;

wherein,

the plant biomass comprises the psilocybin mushroom and the cannabis in a weight ratio of 1:99 to 25:75, respectively.

2. The method of claim 1 , wherein the psilocybin mushroom comprises at least one of Copelandia, Gymnopilus, Inocybe, Panaeolus, Pholiotina, Pluteus , and Psilocybe.

3. The method of claim 1 , wherein the cannabis comprises at least one of Cannabis sativa, Cannabis indica , and Cannabis ruderalis.

4. The method of claim 1 , wherein the psilocybin mushroom has a moisture content of less than 15 wt. %.

5. The method of claim 1 , wherein the cannabis has a moisture content of less than 15 wt. %.

6. The method of claim 1 , wherein the psilocybin mushroom is reduced to a size such that at least 90 wt. % of the psilocybin mushroom present in the plant biomass is less than 10 mm.

7. The method of claim 1 , wherein the cannabis is reduced to a size such that at least 90 wt. % of the cannabis present in the plant biomass is less than 50 mm.

8. The method of claim 1 , wherein the reducing the size of the plant biomass comprises at least one of blending, grinding, pulverizing, mincing, liquefying, cutting, macerating, and chopping.

9. The method of claim 1 , wherein the ultrasonicating employs high-power ultrasound waves effective to achieve ultrasound-assisted cell lysis.

10. The method of claim 1 , wherein the contacting of the plant biomass with the supercritical fluid solvent system is a supercritical fluid extraction (SFE), carried out once.

11. The method of claim 1 , wherein the contacting of the plant biomass with the supercritical fluid solvent system is a fractional supercritical fluid extraction (FSFE), carried out multiple times.

12. The method of claim 1 , wherein the contacting of the plant biomass with the supercritical fluid solvent system is carried out at a pressure of above 74 bar and wherein the supercritical fluid solvent system comprises carbon dioxide (CO 2 ).

13. The method of claim 1 , wherein the contacting of the plant biomass with the supercritical fluid solvent system is carried out at a temperature of above 31° C. and wherein the supercritical fluid solvent system comprises carbon dioxide (CO 2 ).

14. The method of claim 1 , wherein the contacting the plant biomass with the supercritical fluid solvent system is carried out for period of time of at least 60 seconds.

15. The method of claim 1 , wherein the supercritical fluid solvent system comprises carbon dioxide (CO 2 ) and at least one of hydrogen (H 2 ), neon (Ne), nitrogen (N 2 ), argon (Ar), methane (CH 4 ), ethane (CH 3 CH 3 ), propane (CH 3 CH 2 CH 3 ), ammonia (NH 3 ), xenon (Xe), methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran (THF), 1,4-dioxane, acetonitrile, acetic acid, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide (DMSO), formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane (Freon® 23), nitrous oxide (N 2 O), sulfur hexafluroide (SF 6 ), butane (n-C 4 H 10 ), isobutane (i-C 4 H 10 ), ethyl ether ((C 2 H 5 ) 20 ), benzotrifluoride (C 6 H 5 CF 3 ), (p-chlorophenyl)trifluoromethane (ClC 6 H 4 CF 3 ), chlorofluorocarbon (CFC), hydrofluorocarbon (HFA), and HFA-134a (1,1,1,2-tetrafluoroethane).

16. The method of claim 1 , wherein the supercritical fluid solvent system comprises carbon dioxide (CO 2 ) as the sole solvent.

17. The method of claim 1 , further comprising purifying the extract.

18. The method of claim 1 , further comprising purifying the extract employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization (freeze drying), and sublimation.

19. The method of claim 1 , wherein relative to the plant biomass, the extract is enriched with cannabinoids.

20. The method of claim 1 , wherein relative to the plant biomass, the extract is enriched with at least one of psilocybin, psilocin, and baeocystin.

21. The method of claim 1 , wherein relative to the plant biomass, the extract is enriched with terpenes.

22. The method of claim 1 , wherein relative to the plant biomass, the extract is enriched with flavonoids.

23. A method for obtaining an extract, the method comprising:

(a) reducing the size of a plant biomass, the plant biomass comprising psilocybin mushroom and cannabis;

(b) ultrasonicating the plant biomass;

(c) contacting for period of time of at least 60 seconds the plant biomass with a supercritical fluid solvent system that comprises carbon dioxide (CO 2 ), at a pressure of above 74 bar, and at a temperature of above 31° C.; and

(d) removing the supercritical fluid solvent system from the plant biomass to obtain an extract of psilocybin mushroom and cannabis;

wherein,

relative to the plant biomass, the extract is enriched with cannabinoids;

relative to the plant biomass, the extract is enriched with at least one of psilocybin, psilocin, and baeocystin;

relative to the plant biomass, the extract is enriched with terpenes; and

relative to the plant biomass, the extract is enriched with flavonoids.

24. The method of claim 23 , wherein

relative to the cannabis , the extract is enriched with cannabinoids;

relative to the cannabis , the extract is enriched with terpenes;

relative to the cannabis , the extract is enriched with flavonoids; and

relative to the psilocybin mushroom, the extract is enriched with at least one of psilocybin, psilocin, and baeocystin.

25. The method of claim 23 , wherein on a weight percentage basis

relative to the cannabis , the extract comprises at least 25 wt. % more cannabinoids;

relative to the cannabis , the extract comprises at least 25 wt. % more terpenes;

relative to the cannabis , the extract comprises at least 25 wt. % more flavonoids; and

relative to the psilocybin mushroom, the extract comprises in the aggregate at least 25 wt. % more psilocybin, psilocin, and baeocystin.

Assignments (5)
LIEN Recorded Jan 28, 2025
From: CURE PHARMACEUTICAL, INC.
To: CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V.
Reel/Frame 070027/0201 →
CHANGE OF NAME Recorded Jul 17, 2023
From: TF TECH VENTURES, INC.
To: CURE PHARMACEUTICAL, INC.
Reel/Frame 064286/0450 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2023
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES, INC.
Reel/Frame 064256/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES
Reel/Frame 060598/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: DAVIDSON, ROBERT; GIGI, VERED; BERNARDO, JOSE
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 059885/0287 →
Continuity (2)
Provisional Application 62985474 · Mar 5, 2020
Related Publication 20210275618A1 · Sep 9, 2021